Q1 2025 Holdings
Filed 2025-05-15 | 89 holdings | $9.0B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| BeiGene, Ltd.(ONC) | SPONSORED ADR | 07725L102 | $2.4B | 8,799,053 | 26.5% |
| Incyte Corporation(INCY) | COM | 45337C102 | $1.9B | 30,739,953 | 20.6% |
| Acadia Pharmaceuticals Inc.(ACAD) | COM | 004225108 | $712.2M | 42,877,916 | 7.9% |
| Madrigal Pharmaceuticals, Inc.(MDGL) | COM | 558868105 | $654.0M | 1,974,590 | 7.2% |
| Summit Therapeutics Inc.(SMMT) | COM | 86627T108 | $471.2M | 24,424,865 | 5.2% |
| Insmed Incorporated(INSM) | COM PAR $.01 | 457669307 | $410.5M | 5,380,626 | 4.5% |
| Rhythm Pharmaceuticals, Inc.(RYTM) | COM | 76243J105 | $296.9M | 5,604,483 | 3.3% |
| Revolution Medicines, Inc.(RVMD) | COM | 76155X100 | $280.7M | 7,936,972 | 3.1% |
| Kymera Therapeutics, Inc.(KYMR) | COM | 501575104 | $164.1M | 5,995,929 | 1.8% |
| Alkermes plc(ALKS) | SHS | G01767105 | $148.0M | 4,483,285 | 1.6% |
| Edgewise Therapeutics, Inc.(EWTX) | COM | 28036F105 | $135.4M | 6,155,940 | 1.5% |
| Replimune Group, Inc.(REPL) | COM | 76029N106 | $107.7M | 11,045,336 | 1.2% |
| Insmed Incorporated | Note 0.75% 6/1/2028 | 457669AB5 | $101.6M | $42,850,000 | 1.1% |
| Immunovant, Inc.(IMVT) | COM | 45258J102 | $93.3M | 5,457,881 | 1.0% |
| Bicycle Therapeutics plc(BCYC) | SPONSORED ADS | 088786108 | $92.4M | 10,885,357 | 1.0% |
| Immunocore Holdings plc(IMCR) | ADS | 45258D105 | $68.9M | 2,322,656 | 0.8% |
| Kiniksa Pharmaceuticals International, plc(KNSA) | ORD SHS CL A | G52694109 | $62.6M | 2,818,323 | 0.7% |
| AbCellera Biologics Inc.(ABCL) | COM | 00288U106 | $61.4M | 27,525,640 | 0.7% |
| Ultragenyx Pharmaceutical Inc.(RARE) | COM | 90400D108 | $57.1M | 1,576,114 | 0.6% |
| Denali Therapeutics Inc.(DNLI) | COM | 24823R105 | $50.7M | 3,731,695 | 0.6% |
| Kodiak Sciences Inc.(KOD) | COM | 50015M109 | $48.6M | 17,310,490 | 0.5% |
| Nurix Therapeutics, Inc.(NRIX) | COM | 67080M103 | $46.1M | 3,882,125 | 0.5% |
| argenx SE(ARGX) | SPONSORED ADR | 04016X101 | $46.0M | 77,760 | 0.5% |
| Entrada Therapeutics, Inc.(TRDA) | COM | 29384C108 | $44.0M | 4,865,819 | 0.5% |
| Celcuity Inc.(CELC) | COM | 15102K100 | $43.0M | 4,257,735 | 0.5% |
| Grail, Inc.(GRAL) | COM | 384747101 | $41.6M | 1,630,125 | 0.5% |
| Roivant Sciences Ltd.(ROIV) | SHS | G76279101 | $38.0M | 3,767,773 | 0.4% |
| Immatics N.V.(IMTX) | SHS | N44445109 | $32.8M | 7,275,830 | 0.4% |
| Stoke Therapeutics, Inc.(STOK) | COM | 86150R107 | $30.8M | 4,633,838 | 0.3% |
| Cerus Corporation(CERS) | COM | 157085101 | $26.9M | 19,351,087 | 0.3% |
| Vaxcyte, Inc.(PCVX) | COM | 92243G108 | $24.2M | 640,885 | 0.3% |
| Monte Rosa Therapeutics, Inc.(GLUE) | COM | 61225M102 | $22.8M | 4,916,095 | 0.3% |
| Crispr Therapeutics AG(CRSP) | NAMEN AKT | H17182108 | $22.3M | 654,099 | 0.2% |
| Akero Therapeutics, Inc.(AKRO) | COM | 00973Y108 | $22.2M | 548,713 | 0.2% |
| Sera Prognostics, Inc.(SERA) | CLASS A COM | 81749D107 | $20.2M | 5,498,170 | 0.2% |
| Centessa Pharmaceuticals plc(CNTA) | SPONSORED ADS | 152309100 | $17.6M | 1,227,178 | 0.2% |
| Neurogene Inc.(NGNE) | COM | 64135M105 | $17.4M | 1,486,200 | 0.2% |
| Ideaya Biosciences, Inc.(IDYA) | COM | 45166A102 | $17.4M | 1,062,123 | 0.2% |
| Verona Pharma plc(VRNA) | SPONSORED ADS | 925050106 | $14.2M | 223,843 | 0.2% |
| Candel Therapeutics, Inc.(CADL) | COM | 137404109 | $13.8M | 2,437,189 | 0.2% |
| Praxis Precision Medicines, Inc.(PRAX) | COM | 74006W207 | $12.6M | 331,533 | 0.1% |
| 2seventy bio, Inc.(TSVT*) | COMMON STOCK | 901384107 | $12.3M | 2,497,526 | 0.1% |
| Xenon Pharmaceuticals Inc.(XENE) | COM | 98420N105 | $11.7M | 347,408 | 0.1% |
| Bicara Therapeutics Inc.(BCAX) | COM | 055477103 | $10.9M | 833,333 | 0.1% |
| Ionis Pharmaceuticals, Inc.(IONS) | COM | 462222100 | $10.8M | 357,915 | 0.1% |
| DBV Technologies S.A.(DBVT) | SPONSORED ADS | 23306J309 | $10.0M | 1,461,425 | 0.1% |
| Alumis Inc.(ALMS) | COM | 022307102 | $9.6M | 1,562,500 | 0.1% |
| Merus N.V. | COM | N5749R100 | $9.4M | 223,500 | 0.1% |
| Prelude Therapeutics Inc.(PRLD) | COM | 74065P101 | $7.8M | 10,123,824 | 0.1% |
| Verve Therapeutics, Inc. | COM | 92539P101 | $7.7M | 1,691,530 | 0.1% |